Abstract

Neuromuscular electrical stimulation (NMES) elicits muscle contraction and has been shown to improvement of quality of life. However, if NMES improvement the quality of life and attenuate the inflammation is not fully understood. Therefore, our aim sought to assess the effects of short-term of intradialytic NMES on inflammation and quality of life in patients with chronic kidney disease patients undergoing hemodialysis. A randomized clinical trial conducted with parallel design enrolled adult hemodialysis patients three times a week during 1 month. Patients were randomly assigned to two groups (control group, n = 11; 4F/7 M) or (NMES group, n = 10; 4F/6 M). Pre-and post-intervention, was measured the high-sensitivity C reactive protein, interleukin-6, interleukin-10, and TNFα by the ELISA, and quality of life was applied using the SF-36. During each hemodialysis session, NMES was applied bilaterally at thigh and calves for 40 min. There was not change in cytokines (hs-CRP, IL-6, IL-10, and TNFα) concentrations time × group interaction. In addition, no difference was found in eight domains of quality of life. In addition, the groups did not differ for muscle strength and muscle mass. In conclusion, we found that intradialytic NMES did not change inflammation neither quality of life.

Highlights

  • Neuromuscular electrical stimulation (NMES) elicits muscle contraction and has been shown to improvement of quality of life

  • Patients with chronic kidney disease (CKD) undergoing hemodialysis (HD) experiences increase of inflammatory cytokines that are associated with the diminished ­appetite[1] and reduced physical mobility which leads to significant loss of quality of life (QoL)[2,3,4,5]

  • To the best of the author’s knowledge, this study to assess the effects of intradialytic NMES on inflammatory cytokines and QoL

Read more

Summary

Introduction

Neuromuscular electrical stimulation (NMES) elicits muscle contraction and has been shown to improvement of quality of life. Our aim sought to assess the effects of short-term of intradialytic NMES on inflammation and quality of life in patients with chronic kidney disease patients undergoing hemodialysis. Patients with chronic kidney disease (CKD) undergoing hemodialysis (HD) experiences increase of inflammatory cytokines that are associated with the diminished ­appetite[1] and reduced physical mobility which leads to significant loss of quality of life (QoL)[2,3,4,5]. We hypothesized that intradialytic NMES would attenuate the inflammation and improvement the QoL in patients undergoing HD.

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.